H.C. Wainwright analyst Emily Bodnar downgraded IO Biotech (IOBT) to Neutral from Buy with no price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- FDA Recommends Against IO Biotech’s Cylembio Application
- IO Biotech says FDA reccomends not submitting BLA based on IOB-013 trial data
- IO Biotech implements plan to conserve capital, 50% reduction in full-time staff
- IO Biotech Reports Q2 2025 Financial Results
- IO Biotech’s Cylembio Shows Promise Despite Missed Endpoint, Buy Rating Affirmed